| Identification | Back Directory | [Name]
(1S,2R,3S,4R,5S)-4-[6-[[(3-Chlorophenyl)methyl]amino]-2-[2-(3,4-difluorophenyl)ethynyl]-9H-purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide | [CAS]
1377273-00-1 | [Synonyms]
MRS 5698
(1S,2R,3S,4R,5S)-4-[6-[[(3-Chlorophenyl)methyl]amino]-2-[2-(3,4-difluorophenyl)ethynyl]-9H-purin-9-yl]-2,3-dihydroxy-N-methylbicyclo[3.1.0]hexane-1-carboxamide | [Molecular Formula]
C28H23ClF2N6O3 | [MDL Number]
MFCD30182293 | [MOL File]
1377273-00-1.mol | [Molecular Weight]
564.97 |
| Hazard Information | Back Directory | [Uses]
MRS 5698, is a selective A3 adenosine receptor agonist, that reverses mechanoallodynia in several neuropathic pain models in vivo, and it’s orally bioavailable. | [in vivo]
MRS5698 (3 nmol/day; intrathecal injection for 25 days) prevents Oxaliplatin-induced mechano-allodynia and hyperalgesia, and attenuates Oxaliplatin-induced NLRP3/IL-1β neuroinflammation[2].
MRS5698 (1 mg/kg; i.p. at days 2, 3 ) reduces the IL-23 induced (IL23 injected in day 0, 1, 3) ear thickness of C57BL/6N mouse during the third and fourth experimental days[3]. | Animal Model: | Oxaliplatin-induced Male Sprague Dawley rats (200–250 g starting weight)[2] | | Dosage: | 3 nmol/day | | Administration: | Intrathecal injection for 25 days | | Result: | Increased the value of mechanical paw withdrawal threshold in grams (PWT) in rat.
Attenuated oxaliplatin-induced expression of NLRP3 and maturation of caspase 1 in the DH-SC.
Reduced IL-1β levels in the spinal cord.
|
| [IC 50]
Adenosine A3 receptor: ~3 nM (Ki) | [storage]
Store at -20°C |
|
| Company Name: |
BOC Sciences
|
| Tel: |
|
| Website: |
https://www.bocsci.com |
|